BGB-283: Clinical Trials

3 trials of BGB-283, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3

Follow BGB-283: new trials by email Literature Review of BGB-283 trials Research Report on BGB-283

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Lifirafenib, mirdametinib - Solid Tumor, Adult
Phase 1CompletedBeiGene912019-05-012026-01-07
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
BGB-283 - Solid Tumors
Phase 1CompletedBeiGene422015-10-122024-10-23
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
BGB-283 - Solid Tumors
Phase 1CompletedBeiGene1312013-11-202024-12-27

Sponsors

BeiGene (3)

Countries

Australia (2)  ·  China (1)  ·  New Zealand (1)  ·  United States (1)

Top investigators

Jayesh Desai, MD (1)  ·  Xiang Li, MD (1)

Results publications

PMID 32182156